Elevating Patient Representation in Clinical Trials as a CRO
In Conversation with Daniel Perez
The importance of patient representation in clinical trials cannot be overstated. It is crucial to ensure that medical advancements benefit all populations equally. Both pharmaceutical companies and Clinical Research Organizations (CROs) bear the responsibility of promoting inclusion and play a critical role in achieving this goal.
Turning the Patient Representation Spotlight
To gain a deeper understanding of the current state of clinical trials and ongoing advancements as it relates to patient representation, Ryan Brown at H1 interviewed Daniel Perez, Global Head of Health Equity Strategy at Worldwide Clinical Trials.
Perez, a trailblazer in health equity and diversity, brings his wealth of experience and insights to the forefront. He advocates for innovative approaches to ensure inclusivity and representation in clinical trial populations.
The interview covers:
- Why patient representation is important when thinking about a CRO versus a pharma company
- Whether technology plays a role in promoting inclusion
- What impact H1 has on helping life sciences companies improve patient representation
Watch the interview:
Technology to Transform Health Equity
H1’s Clinical solutions redefine efficiency for CROs and pharma companies in promoting representation in clinical trials through the identification of inclusive investigators, patient groups, and top trial sites, enhancing trial representation. Request a demo to learn more.
